The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).
 
Jennifer Rachel Eads
Employment - Janssen Oncology (I); Merus (I)
Stock and Other Ownership Interests - Janssen Oncology (I); Merus (I)
Consulting or Advisory Role - Daiichi Sankyo; Daiichi Sankyo; Exelixis; Merck; Oncolys BioPharma
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Gilead Sciences (Inst); Hutchison MediPharma (Inst); Merck (Inst); Oncolys BioPharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology (I)
 
Noah Graham
No Relationships to Disclose
 
Michael K. Gibson
Honoraria - Astellas Pharma; Coherus Biosciences; Daiichi Sankyo/Lilly; Regeneron
Consulting or Advisory Role - Abbvie; regeneron; UpToDate
Research Funding - Daiichi Sankyo/Lilly (Inst); PapiVax Biotech, Inc. (Inst)
 
Lakshmi Rajdev
Consulting or Advisory Role - Amgen
 
Anuradha Bapsi Chakravarthy
Consulting or Advisory Role - Merck
 
Onkar V Khullar
No Relationships to Disclose
 
Steven H. Lin
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - SEEK Diagnostics
Honoraria - AstraZeneca/MedImmune; BeyondSpring Pharmaceuticals
Research Funding - BeyondSpring Pharmaceuticals; Nektar; STCube Pharmaceuticals Inc.
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Lilly; Flame Biosciences; Genentech/Roche; GlaxoSmithKline; Guardant Health; Janssen; Merck; Merus; MSD Oncology; Novartis; OncoCyte; Pfizer; Regeneron; Sanofi
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Merck; Merus; MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Adaptive Biotechnologies (Inst); Akoya Biosciences (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Takeda (Inst)
 
Rajiv Agarwal
Honoraria - HMP Education; NCCN; OncLive/MJH Life Sciences
 
Michael Blazar
No Relationships to Disclose
 
Dhaval R. Mehta
Stock and Other Ownership Interests - Abbvie; Lilly
Honoraria - Cardinal Health; Curio Science; IntegraConnect
Consulting or Advisory Role - AstraZeneca; BeiGene; Daiichi Sankyo/Astra Zeneca; Janssen Biotech
 
Tareq Al Baghdadi
Stock and Other Ownership Interests - Bristol-Myers Squibb; Epizyme; HERON
Honoraria - Cardinal Health
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cardinal Health; Genentech/Roche; Kite, a Gilead company; Lilly
 
Ning Jin
No Relationships to Disclose
 
Ryan Campbell Massa
No Relationships to Disclose
 
Stanley R. Hamilton
Research Funding - CytoImmune Therapeutics (Inst); Intima (Inst); Iovance Biotherapeutics (Inst); Minerva Biotechnologies (Inst)
 
Charles A. Staley
No Relationships to Disclose
 
Terence Z. Wong
Consulting or Advisory Role - GE Healthcare; Novartis; Progenics; Telix Pharmaceuticals
Research Funding - Blue Earth Diagnostics (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Progenics
 
Peter J. O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)